Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancy.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008524:Medrogestone / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology; D010298:Parity; D011245:Pregnadienes / Q000627:therapeutic use*; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects; D011372:Progestins / Q000627:therapeutic use*; D012008:Recurrence; D012509:Sarcoma / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology
D011245:Pregnadienes; D011372:Progestins; D008524:Medrogestone; D011374:Progesterone; D003520:Cyclophosphamide; D005472:Fluorouracil